Dossier
outlicensing agreements
Coverage of outlicensing agreements in the Nexus archive.
- Which company could become the Chinese Pfizer? Here are analysts’ top picks
Chinese biotechnology companies are projected to market their own medications in Europe and the US within 10 to 15 years, according to analysts. Discussions among investors and analysts focus on identifying which firms will achieve international sales amid a boom in outlicensing agreements.
- Which company could become the Chinese Pfizer? Here are analysts’ top picks
Chinese biotechnology companies may begin selling their own drugs in Europe and the US within 10 to 15 years, according to policy and industry analysts. Discussions among investors and analysts focus on which companies will achieve international brand recognition through outlicensing agreements.